For research use only. Not for therapeutic Use.
Latamoxef（Cat No.:I007623）is a broad-spectrum, third-generation cephalosporin antibiotic effective against a wide range of Gram-negative and some Gram-positive bacteria. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, resulting in bacterial cell lysis and death. Latamoxef is particularly valuable for treating severe infections, including respiratory, urinary tract, and intra-abdominal infections. It is also known for its activity against anaerobic bacteria, which distinguishes it from many other cephalosporins. Latamoxef is primarily used in hospital settings and remains significant in studies focused on combating antibiotic-resistant pathogens.
| Catalog Number | I007623 |
| CAS Number | 64952-97-2 |
| Synonyms | Latamoxef, Moxalactam, Lamoxactam, Festamoxin, 6059-S;(6R,7R)-7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| Molecular Formula | C20H20N6O9S |
| Purity | ≥95% |
| Target | Beta-lactamase |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term , or -20°C for long term. |
| IUPAC Name | (6R,7R)-7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| InChI | InChI=1S/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)/t12?,18-,20+/m1/s1 |
| InChIKey | JWCSIUVGFCSJCK-CAVRMKNVSA-N |
| SMILES | CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)O)OC)OC2)C(=O)O |
| Reference | </br>1:Clinical ineffectiveness of latamoxef for Stenotrophomonas maltophilia infection. Hagiya H, Tasaka K, Sendo T, Otsuka F.Infect Drug Resist. 2015 Oct 20;8:353-7. doi: 10.2147/IDR.S90726. eCollection 2015. PMID: 26527890 Free PMC Article</br>2:Potent antibacterial activities of latamoxef (moxalactam) against ESBL producing Enterobacteriaceae analyzed by Monte Carlo simulation. Ito A, Tatsumi Y, Wajima T, Nakamura R, Tsuji M.Jpn J Antibiot. 2014 Apr;67(2):109-22. PMID: 24956910 </br>3:Phosphate deprivation is associated with high resistance to latamoxef of gel-entrapped, sessile-like Escherichia coli cells. Vilain S, Cosette P, Junter GA, Jouenne T.J Antimicrob Chemother. 2002 Feb;49(2):315-20. PMID: 11815573 </br>4:[Polarographic behavior of latamoxef sodium and its trace determination]. Gu HY, Sun DM, Yu AM, Chen HY.Yao Xue Xue Bao. 1997 May;32(5):373-6. Chinese. PMID: 11498875 </br>5:Comparison of flomoxef with latamoxef in the treatment of sepsis and/or Gram-negative bacteremia in adult patients. Chen YC, Hung CC, Lin SF, Chang SC, Hsieh WC.Int J Antimicrob Agents. 1996 May;7(1):69-74. PMID: 18611739 </br>6:In-vitro evaluation of beta-lactamase inhibition by latamoxef and imipenem. Sotto A, Brunschwig C, O/’Callaghan D, Ramuz M, Jourdan J.J Antimicrob Chemother. 1996 Apr;37(4):697-701. PMID: 8722535 </br>7:Sequential changes in the prostatic fluid level of latamoxef in patients with acute bacterial prostatitis. Itoh M, Katoh N, Ono Y, Ohshima S, Miyake K.Urol Int. 1995;55(2):101-4. PMID: 8533190 </br>8:Improvement of the rectal bioavailability of latamoxef sodium by adjuvants following administration of a suppository. Nakanishi K, Masukawa T, Masada M, Nadai T.Biol Pharm Bull. 1994 Nov;17(11):1496-500. PMID: 7703971 </br>9:[Revaluation of current antimicrobials. Series 16: Latamoxef sodium]. Kumazawa J, Shinagawa N.Jpn J Antibiot. 1994 Oct;47(10):1259-66. Review. Japanese. No abstract available. PMID: 7807687 </br>10:Ceftriaxone versus latamoxef in febrile neutropenic patients: empirical monotherapy in patients with solid tumours. Oturai PS, Holländer NH, Hansen OP, Boas J, Bruun BG, Frimodt-Møller N, Dombernowsky P, Hansen HH.Eur J Cancer. 1993;29A(9):1274-9. PMID: 8343267 |
